跳至主要内容
临床试验/JPRN-UMIN000021250
JPRN-UMIN000021250已完成2 期

A prospective randomized controlled trial of selective DEB-epiDOX vs. selective conventional TACE for hepatocellular carcinoma focusing on local complete response rate - A randomized controlled trial of selective DEB-TACE vs. cTACE for HCC (JIVROSG-1302:PRESIDENT study)

Japan Interventional Radiology In Oncology Study Group(JIVROSG)0 个研究点目标入组 440 人开始时间: 2016年3月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
440

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Tumor thrombosis in portal vein 2. Extrahepatic metastasis 3. Ruptured HCC nodules in which TACE is planned 4. Extrahepatic feeding arteries for HCC nodules in which TACE is planned 5. Prior surgical reconstruction or endoscopic treatment of the biliary tract 6. Clinically significant refractory ascites or pleural effusion 7. Severe arterio-portal or arterio-venous shunts in the liver 8. Allergy to contrast medium that precludes angiography 9. Previously registered patients in this study 10. Severe, active co-morbidity 11. Pregnancy, nursing women, or women of childbearing potential, and men who are sexually active and not willing or able to use medically acceptable forms of contraception 12. Not eligible because of safety issues judged by investigators

研究者

发起方
Japan Interventional Radiology In Oncology Study Group(JIVROSG)

相似试验